Eli Lilly (LLY) +7.4% premarket after two large studies show its experimental Alzheimer’s...


Eli Lilly (LLY) +7.4% premarket after two large studies show its experimental Alzheimer’s treatment slowed the decline of cognition in some patients, although it failed to meet its primary goals. The finding that the drug slowed the worsening of mental loss in mild to moderate patients wasn’t expected by analysts, who had given the drug a less than 20% chance of showing a benefit.

From other sites
Comments (1)
  • tampabay
    , contributor
    Comments (439) | Send Message
     
    Wish I would have bought more LLY..but I FORGOT!
    24 Aug 2012, 09:39 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs